GT Medical Technologies Welcomes Two New C-Suite Members

GT Medical Technologies Inc. (GT MedTech), has recruited two new managers to its to top executive team: Tom Moore as chief commercial officer and Sandeep Yadav as chief financial officer. 

“We’re thrilled to add two leaders with Tom and Sandeep to our senior leadership team,” GT MedTech CEO Per Langoe said. “Tom’s ability to develop effective commercial strategies will help accelerate the adoption of GammaTile across the country, while Sandeep’s expertise in our industry will ensure the company’s financial health and continued growth.”

Moore brings to his new position more than two decades of experience in healthcare, having led sales and marketing efforts for seven novel therapies in the United States and Europe. Moore’s medtech career began at Medtronic, where he held leadership roles in sales and marketing. Prior to joining GT MedTech, he was on the executive leadership teams at CVRx and Ablative Solutions.

“GammaTile has one of the most compelling stories for its impact on patients suffering from new and recurrent brain tumors,” Moore said. “I look forward to working closely with the leadership team to bring GammaTile to reach its full potential as we expand our reach beyond the more than 1,400 patients already treated.” 

With more than two decades of experience in finance, data analytics, operations, and strategic leadership, Yadav will lead GT MedTech’s financial operations. Yadav has held senior roles at CardioMEMS, Qardio, Profusa, and Cardian, where he led transformative initiatives including implementing advanced data analytics, enhancing accounting systems, and securing significant investments. 

“I am thrilled to join GT Medical Technologies at this pivotal moment in its journey. The innovative work being done with GammaTile has the potential to revolutionize the treatment of brain tumors and significantly improve patient outcomes,” Yadav stated. “I am excited to work with the professionals at GT Medical Technologies to drive our mission forward and achieve advancements in medical technology.”

Driven to raise the standard of care and improve the lives of patients with brain tumors, a team of brain tumor specialists formed GT Medical Technologies. GammaTile is U.S. Food and Drug Administration-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms. Since its full market release in the United States in March 2020, GammaTile has been offered in more than 100 institutions, with more centers being added each month.